Innoviva, Inc.: insider trades · United States · SEC (Form 4)

About Innoviva, Inc.

Innoviva, Inc. is a United States-based biopharmaceutical company listed on the NASDAQ (United States). Its business model is unusual for the pharma sector because it combines royalty income, a hospital-focused specialty therapeutics platform, and a portfolio of strategic healthcare investments. The company was originally incorporated in 1996 as Advanced Medicine, Inc., later operated under the Theravance name, and was rebranded as Innoviva in 2016. Its headquarters are in Burlingame, California. Innoviva was initially formed to maximize the value of royalty streams from respiratory products co-developed with and licensed to GSK. Over time, management broadened the strategy beyond passive royalty collection toward a more active healthcare asset platform. Today the company is organized around three main pillars. First, it owns a durable royalty portfolio tied to legacy respiratory medicines associated with GSK. Second, it operates Innoviva Specialty Therapeutics (IST), a commercial platform focused on critical care and infectious disease. Third, it holds strategic investments in healthcare-related assets, which adds optionality and may support long-term capital appreciation. From a product perspective, IST markets GIAPREZA®, XERAVA®, XACDURO®, and ZEVTERA®, and the business recently added NUZOLVENCE® following U.S. regulatory approval. This gives Innoviva exposure to unmet medical needs in hospital care and anti-infective therapy, areas where clinical differentiation and regulatory barriers matter more than pure scale. The competitive environment is still intense, especially in infectious diseases, but Innoviva’s portfolio is differentiated by a mix of legacy royalties and newly commercialized specialty products rather than dependence on a single drug. Geographically, the company remains primarily U.S.-centric, with most operations and revenue generation anchored in the United States, although some products and licensing relationships can have broader international relevance depending on the asset and indication. Recent milestones are important for investors: in February 2026, Innoviva reported full-year 2025 results showing revenue growth and higher net income; it highlighted the mid-2025 U.S. launch of ZEVTERA; and it disclosed FDA approval of NUZOLVENCE in late 2025. Innoviva also initiated a $125 million share repurchase program, which may be of particular interest to investors tracking insider ownership changes and SEC Form 4 activity.